Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Financial Summary for [[ item.sessionDateDisplayLong ]]
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Fiscal Year End Date: 12/31

(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Sales 22,471,000 22,447,000 21,383,000 13,532,000 21,351,000
Sales Growth +0.11% +4.98% +58.02% -36.62% -16.37%
Net Income 2,694,000 4,686,000 3,255,000 4,049,000 26,028,000
Net Income Growth -42.51% +43.96% -19.61% -84.44% +405.99%
(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Total Assets 178,287,000 181,088,000 171,966,000 167,558,000 166,061,000
Total Assets Growth -1.55% +5.30% +2.63% +0.90% -13.37%
Total Liabilities 108,129,000 109,550,000 101,946,000 98,784,000 94,833,000
Total Liabilities Growth -1.30% +7.46% +3.20% +4.17% -17.73%
(Values in U.S. Thousands) Sep, 2024 Jun, 2024 Mar, 2024 Dec, 2023 Sep, 2023
Operating Cash Flow 17,283,000 9,290,000 3,657,000 22,791,000 14,928,000
Operating Cash Flow Growth +86.04% +154.03% -83.95% +52.67% +100.67%
Net Cash Flow -1,879,000 3,019,000 3,614,000 7,732,000 5,601,000
Change in Net Cash Flow -162.24% -16.46% -53.26% +38.05% -20.62%
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar